
Loading, please wait...

Loading, please wait...

A systematic review and meta-analysis examined active fluid de-resuscitation strategies in patients with septic shock, including diuretics and active fluid removal. The review included 13 studies, with five randomised controlled trials contributing to the quantitative analysis. The evidence did not show a mortality benefit from active de-resuscitation compared with usual care. Although some studies achieved greater fluid separation, patient-centred outcomes were generally unchanged, and the evidence base was limited by small samples and heterogeneity in the interventions used. The paper is highly relevant to CritiCARE's focus on de-resuscitation and fluid stewardship. It reinforces a key distinction: reducing a patient's fluid balance is not automatically the same as improving survival. For clinicians, active fluid removal should therefore be linked to an identifiable clinical problem such as fluid overload, venous congestion or failure to tolerate additional fluid—not simply to a desire to make the balance more negative. The practical approach is phase-based resuscitation: give fluid when there is a clear indication, reassess whether the patient remains fluid responsive, and consider fluid removal once the haemodynamic objective has been achieved and congestion becomes harmful. The review supports careful, patient-specific de-resuscitation while highlighting the need for better randomised evidence.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A systematic review and meta-analysis examined active fluid de-resuscitation strategies in patients with septic shock, including diuretics and active fluid removal. The review included 13 studies, with five randomised controlled trials contributing to the quantitative analysis. The evidence did not show a mortality benefit from active de-resuscitation compared with usual care. Although some studies achieved greater fluid separation, patient-centred outcomes were generally unchanged, and the evidence base was limited by small samples and heterogeneity in the interventions used. The paper is highly relevant to CritiCARE's focus on de-resuscitation and fluid stewardship. It reinforces a key distinction: reducing a patient's fluid balance is not automatically the same as improving survival. For clinicians, active fluid removal should therefore be linked to an identifiable clinical problem such as fluid overload, venous congestion or failure to tolerate additional fluid—not simply to a desire to make the balance more negative. The practical approach is phase-based resuscitation: give fluid when there is a clear indication, reassess whether the patient remains fluid responsive, and consider fluid removal once the haemodynamic objective has been achieved and congestion becomes harmful. The review supports careful, patient-specific de-resuscitation while highlighting the need for better randomised evidence.
4 weeks back

Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week

Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back

A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back

A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month

Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back